RxDoctor Payments Data

William Bennett, MD

Interventional Cardiology · Spokane, WANPI 1396791026

Payments from drug & device makers

$2,005in general payments, 2019–2025

Across 91 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$541
  • Novartis$245
  • Amgen$211
  • Boehringer Ingelheim$204
  • AstraZeneca$139
  • Boston Scientific$128
  • plus $537 from 9 others

What the payments were for

  • Food & beverage$2,005100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,005 in reported general payments places this provider in the 30th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$79,326
Medicare patients
435
Services billed
1,014

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban119$119,509
EntrestoSacubitril/Valsartan118$111,384
XareltoRivaroxaban110$102,253
Repatha SureclickEvolocumab63$41,258
JardianceEmpagliflozin43$35,510
VascepaIcosapent Ethyl19$11,491
Rosuvastatin Calcium216$3,823
Metoprolol Succinate221$3,205
Potassium Chloride177$2,766
Ezetimibe101$2,300
Amlodipine Besylate273$1,852
Losartan Potassium173$1,701
Atorvastatin Calcium149$1,533
Nitroglycerin87$1,198
Diltiazem 24hr Er (Cd)Diltiazem Hcl43$1,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$541$119,509119 claims
NovartisEntresto$245$111,384118 claims
Johnson & JohnsonXarelto$93$102,253110 claims
Boehringer IngelheimJardiance$204$35,51043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →